EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Ritlecitinib for Alopecia Areata in Patients Under 18 Years of Age: A Single-Center Retrospective Real-World Study

Ting Guo, Sijian Wen, Wenjun Zheng

Clinical, Cosmetic and Investigational Dermatology · 2026-11 · Volume 19 · 1-8

DOI: 10.2147/ccid.s624001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical, Cosmetic and Investigational Dermatology, 2026-11. Verfasst von Ting Guo und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Alopecia areata (AA) in pediatric and adolescent patients can be severe and difficult to manage, and real-world data on targeted therapies in this population remain limited. Ritlecitinib, a selective JAK3/TEC inhibitor, has demonstrated efficacy in adults with AA, but evidence in patients under 18 years of age is scarce. The purpose of this study is to assess the real-world effectiveness and safety of ritlecitinib in pediatric and adolescent patients with alopecia areata. Patients and Methods: This retrospective real-world study included patients aged < 18 years with AA treated with ritlecitinib 50 mg once daily. Treatment response was assessed using changes in Severity of Alopecia Tool (SALT) scores and achievement of SALT50/75/90 at the last on-treatment observation. Safety outcomes were evaluated based on clinical records.

Results

Twenty-seven patients were included, with a median age of 9.3 years (IQR, 6.0– 14.6), including patients younger than 12 years who received off-label treatment. The median baseline SALT score was 50. The median SALT score decreased to 0 at the last observation (p < 0.001). SALT50, SALT75, and SALT90 were achieved by 96.3%, 77.8%, and 55.6% of patients, respectively, and 51.9% achieved complete scalp regrowth. Treatment responses were observed in both patchy AA and AT/AU subgroups; however, interpretation of subgroup differences is limited by the small sample sizes. No serious adverse events or treatment discontinuations due to adverse events were documented in the available medical records.

Conclusion

In this single-center retrospective cohort, ritlecitinib treatment was associated with substantial improvement in SALT scores and no documented serious adverse events during the observation period. These preliminary findings warrant confirmation in larger prospective studies, particularly in children younger than 12 years receiving off-label treatment.

Zitieren

APA

Guo, T., Wen, S., & Zheng, W. (2026). Ritlecitinib for Alopecia Areata in Patients Under 18 Years of Age: A Single-Center Retrospective Real-World Study. Clinical, Cosmetic and Investigational Dermatology, Volume 19, 1-8. https://doi.org/10.2147/ccid.s624001

Vancouver

Guo T, Wen S, Zheng W. Ritlecitinib for Alopecia Areata in Patients Under 18 Years of Age: A Single-Center Retrospective Real-World Study. Clinical, Cosmetic and Investigational Dermatology. 2026;Volume 19:1-8. doi:10.2147/ccid.s624001

BibTeX
@article{Guo2026,
  author = {Guo, Ting and Wen, Sijian and Zheng, Wenjun},
  title = {Ritlecitinib for Alopecia Areata in Patients Under 18 Years of Age: A Single-Center Retrospective Real-World Study},
  journal = {Clinical, Cosmetic and Investigational Dermatology},
  year = {2026},
  volume = {Volume 19},
  pages = {1--8},
  doi = {10.2147/ccid.s624001}
}
Kostenlos starten →